Balagurunathan Muruganantham, Natarajan Thrilok, Karthikeyan Jothilakshmi, Palanisamy Venkateshwaran
Department of Pediatrics, PSG Institute of Medical Sciences and Research, Tamilnadu, India.
Clin Exp Pediatr. 2021 Oct;64(10):531-537. doi: 10.3345/cep.2021.00374. Epub 2021 Aug 4.
Multisystem inflammatory syndrome in children (MIS-C) is a new hyperinflammatory variant that evolved during the coronavirus disease 2019 pandemic. Although the precise pathophysiology of MIS-C is uncertain, it is thought to be due to immune dysregulation occurring after recovery from acute infection.
Our study aimed to analyze the clinical spectrum, laboratory parameters, imaging characteristics, treatment strategies, and short-term outcomes of children with a diagnosis of MIS-C.
This retrospective and prospective observational study included children less than 16 years of age who were admitted to the pediatric unit of a tertiary care teaching hospital in south India between August 2020 to January 2021 with a diagnosis of MIS-C according to World Health Organization criteria.
Twenty-one children were included in the analysis; all had fever with variable combinations of other symptoms. The mean age was 6.9 years; 71.4% were male. Gastrointestinal (80.9%) and cardiovascular (80.9%) systems were the most commonly affected. The majority of children had elevated inflammatory markers, and 16 (76.2%) had echocardiographic abnormalities mimicking Kawasaki disease. Eleven children (52.4%) required intensive care admission, 3 (14.3%) required supplemental oxygen, and 4 (19%) required inotropes. Nine (42.9%) were treated with intravenous immunoglobulin alone, 6 (28.6%) with steroids alone, and 3 (14.3%) with steroids and immunoglobulin. The median hospital stay was 6 days; there were no fatalities. Overweight/obesity, elevated ferritin, and mucocutaneous involvement were significantly associated with a prolonged hospital stay (≥7 days). Sixteen children (76.2%) were followed up till now and all of them had no clinical concerns.
MIS-C is an emerging disease with variable presentation. A high index of suspicion is necessary for its early identification and appropriate management. Further research is essential for developing optimal treatment strategies.
儿童多系统炎症综合征(MIS-C)是在2019冠状病毒病大流行期间出现的一种新的过度炎症变体。尽管MIS-C的确切病理生理学尚不确定,但认为它是由于急性感染康复后发生的免疫失调所致。
我们的研究旨在分析诊断为MIS-C的儿童的临床谱、实验室参数、影像学特征、治疗策略和短期结局。
这项回顾性和前瞻性观察性研究纳入了2020年8月至2021年1月期间入住印度南部一家三级护理教学医院儿科病房的16岁以下儿童,这些儿童根据世界卫生组织标准被诊断为MIS-C。
21名儿童纳入分析;所有儿童均有发热及其他症状的不同组合。平均年龄为6.9岁;71.4%为男性。胃肠道(80.9%)和心血管系统(80.9%)是最常受累的系统。大多数儿童炎症标志物升高,16名(76.2%)有类似川崎病的超声心动图异常。11名儿童(52.4%)需要入住重症监护病房,3名(14.3%)需要补充氧气,4名(19%)需要使用血管活性药物。9名(42.9%)仅接受静脉注射免疫球蛋白治疗,6名(28.6%)仅接受类固醇治疗,3名(14.3%)接受类固醇和免疫球蛋白治疗。中位住院时间为6天;无死亡病例。超重/肥胖、铁蛋白升高和黏膜皮肤受累与住院时间延长(≥7天)显著相关。16名儿童(76.2%)至今接受了随访,所有儿童均无临床问题。
MIS-C是一种表现多样的新出现疾病。对其进行早期识别和适当管理需要高度的怀疑指数。开展进一步研究对于制定最佳治疗策略至关重要。